S. Qayyum, Abubakar Habib, Svyatoslav Kechyn, D. Auger, N. Damani, A. Griguer, N. Hadjiloizou, P. Jain, N. Keenan, Masood Khan, Anish Prabhakar, Kevin Rosenfeld, J. Sehmi
{"title":"P01 Heartflow: experience of a high-volume district general hospital","authors":"S. Qayyum, Abubakar Habib, Svyatoslav Kechyn, D. Auger, N. Damani, A. Griguer, N. Hadjiloizou, P. Jain, N. Keenan, Masood Khan, Anish Prabhakar, Kevin Rosenfeld, J. Sehmi","doi":"10.1136/HEARTJNL-2020-BSCI.14","DOIUrl":null,"url":null,"abstract":"Introduction HeartFlow is a non-invasive technique for estimating fractional flow reserve (FFRCT) from computer tomography coronary angiography (CTCA). HeartFlow has been made available via an NHS England funded program since September 2018 and is now fully embedded within our stable chest pain pathway. The aim of this work was to evaluate the impact of HeartFlow, which replaced previous practice of stress testing for patients with moderate coronary lesions, and invasive angiography for those with severe stenoses on CTCA. Methods We reviewed 360 consecutive patients who underwent CTCA and FFRCT between September 2018 and June 2019. CT coronary angiograms and HeartFlow models were read by a cardiologist and radiologist. Clinical records of all patients were reviewed. Results All patients referred for FFRCT had coronary stenoses greater than 50%. 72% had FFRCT≥0.8 and were discharged. 26% had FFRCT Conclusion Our study demonstrates the impact of HeartFlow in a high-volume CTCA service. Two thirds of patients referred for HeartFlow, who would previously have undergone downstream testing, had negative results and the pathway stopped at that point. Of the patients referred for invasive assessment, significant disease was found in two thirds, and in one third significant stenoses were not identified.","PeriodicalId":383700,"journal":{"name":"Scientific poster abstracts","volume":"13 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scientific poster abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/HEARTJNL-2020-BSCI.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Introduction HeartFlow is a non-invasive technique for estimating fractional flow reserve (FFRCT) from computer tomography coronary angiography (CTCA). HeartFlow has been made available via an NHS England funded program since September 2018 and is now fully embedded within our stable chest pain pathway. The aim of this work was to evaluate the impact of HeartFlow, which replaced previous practice of stress testing for patients with moderate coronary lesions, and invasive angiography for those with severe stenoses on CTCA. Methods We reviewed 360 consecutive patients who underwent CTCA and FFRCT between September 2018 and June 2019. CT coronary angiograms and HeartFlow models were read by a cardiologist and radiologist. Clinical records of all patients were reviewed. Results All patients referred for FFRCT had coronary stenoses greater than 50%. 72% had FFRCT≥0.8 and were discharged. 26% had FFRCT Conclusion Our study demonstrates the impact of HeartFlow in a high-volume CTCA service. Two thirds of patients referred for HeartFlow, who would previously have undergone downstream testing, had negative results and the pathway stopped at that point. Of the patients referred for invasive assessment, significant disease was found in two thirds, and in one third significant stenoses were not identified.